ACTR 087/SEA BCMA combination therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameACTR 087/SEA BCMA combination therapy
Drug Alias NameACTR-BCMAACTR087 + SEA-BCMA combination therapyACTR087 + SEA-BCMASEA BCMA/ACTR 087ACTR 087/SEA BCMA
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnum Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSeagen IncUnum Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A